Novo Nordisk Seeks Self-Pay Wegovy Market in Japan to Triple Patients by 2030
Novo Nordisk will roll out self-funded Wegovy treatment pathways in Japan, where only 14,000 of roughly 6 million eligible patients currently access obesity drugs under stringent insurance criteria. The Japan unit posted 5.4% revenue growth last year and targets double-digit gains aiming to triple patient numbers by 2030 via physician and local government programs.
1. New Self-Pay Treatment Pathways
Novo Nordisk will collaborate with physicians and patients to offer Wegovy and other obesity drugs through self-funded channels in Japan. Aimed at those who cannot meet strict reimbursement eligibility, the initiative bypasses insurance to unlock untapped demand.
2. Japan Obesity Drug Market Constraints
Wegovy has been available since February 2024, yet only 14,000 of an estimated 6 million eligible patients receive treatment due to stringent BMI thresholds, prior diet-and-exercise requirements, and limited facility distribution across roughly 1,200 sites.
3. Financial Impact and Growth Strategy
The Japan unit grew revenue by 5.4% last year and targets double-digit growth. Novo Nordisk plans partnerships with medical organizations and local governments, aiming to triple patient numbers by 2030 through awareness campaigns and expanded program access.